

Form 51-102F3

MATERIAL CHANGE REPORT

1. **Name and Address of the Issuer**

Helix Biopharma Corp. (“Helix” or the “Company”)
401 Bay Street, Suite 2704
Toronto, Ontario
M5H 2Y4

2. **Date of Material Change**

December 8, 2022

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated through Newsfile on December 8, 2022 and filed on the system for electronic document analysis and retrieval (SEDAR).

4. **Summary of Material Change**

Changes to the board and management of the Company.

5. **Full Description of Material Change**

The material change is described in the attached News Release.

6. **Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

None.

8. **Executive Officer**

For further information, please contact Hatem Kawar, CFO: 905-841-2300.

9. **Date of Report**

December 15, 2022



2704, 401 Bay Street
Toronto, M5H 2Y4 Ontario
Tel: 905-841-2300
www.helixbiopharma.com

Helix Biopharma Corp. Announces Board & Management Changes

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced changes in its board of directors (the "Board") and management.

The Company is pleased to announce that Mr. Jacek Antas has been appointed as the Company’s CEO to replace Mr. Artur Gabor with immediate effect. Mr. Gabor has resigned as the CEO and a director of the Board of the Company. Mr. Antas has been on the Board of the Company since April 2022. He has more than 25 years of experience in the financial services industry holding various positions in sales and consulting. Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various companies throughout his career.

The Company is also pleased to announce the appointment of Ms. Malgorzata Irena Laube on the Board, with immediate effect. Ms. Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology. Ms. Laube is based in Edmonton, Alberta, Canada.

“On behalf of Helix, I would like to thank Mr. Gabor for his service as the CEO and welcome Mr. Antas to the new role” said Mr. Jerzy Leszczyński, Chair of the Audit Committee. “We are also delighted that Ms. Laube has agreed to join the Board of the Company. The Board and Management team look forward to working with Mr. Antas and Ms. Laube in their new roles.” continued Mr. Leszczyński.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol “HBP”.

For more information, please contact:

Helix BioPharma Corp.
Suite 2704, 401 Bay Street
Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, Corporate Secretary
namrata@grovecorp.ca